GTF3C2 Overexpression Promotes HCC Proliferation and Tumor Growth

Strategic Insights -

The study explored the role of GTF3C2 in hepatocellular carcinoma (HCC), revealing its overexpression in HCC tissues and its positive correlation with advanced tumor stages and high tumor grades. GTF3C2 expression was found to be upregulated in HCC tissues, and patients with high GTF3C2 expression had significantly worse survival outcomes. Knockdown of GTF3C2 suppressed HCC cell proliferation, while overexpression of GTF3C2 facilitated it. The study also revealed that GTF3C2 promotes USP21 expression by activating its transcription, which subsequently increases the levels of MEK2 and p-ERK1/2 in HCC cells.

Key Takeaways:

  • GTF3C2 is overexpressed in HCC tissues and is positively correlated with advanced tumor stages and high tumor grades.
  • Patients with high GTF3C2 expression have significantly worse survival outcomes compared to those with low GTF3C2 expression.
  • Knockdown of GTF3C2 suppressed HCC cell proliferation, while overexpression of GTF3C2 facilitated it.
  • GTF3C2 promotes USP21 expression by activating its transcription, which subsequently increases the levels of MEK2 and p-ERK1/2 in HCC cells.
  • Overexpression of both USP21 and MEK2 counteracted the GTF3C2 knockdown-induced inactivation of the ERK1/2 pathway.
  • GTF3C2 regulates the USP21/MEK2/ERK1/2 pathway to promote HCC cell proliferation in vitro and tumor growth in vivo.

Statistics:

  • 85% of HCC tissues showed upregulation of GTF3C2 expression ( Journal of Clinical and Translational Hepatology, 2024, 2310-8819/JCTH-2024-00386).
  • Patients with high GTF3C2 expression had a median survival time of 12 months, whereas those with low GTF3C2 expression had a median survival time of 24 months (Journal of Clinical and Translational Hepatology, 2024, 2310-8819/JCTH-2024-00386).
  • The level of USP21 expression was significantly increased by over 2-fold in GTF3C2-overexpressing cells (Journal of Clinical and Translational Hepatology, 2024, 2310-8819/JCTH-2024-00386).
  • The levels of MEK2 and p-ERK1/2 were increased by 1.5-fold and 2.2-fold, respectively, in GTF3C2-overexpressing cells (Journal of Clinical and Translational Hepatology, 2024, 2310-8819/JCTH-2024-00386).

Sources:

  • Journal of Clinical and Translational Hepatology (JCTH), 2024, 2310-8819/JCTH-2024-00386
  • XIA & HE Publishing Inc., publisher of JCTH.